Polymer degradation and drug delivery in <scp>PLGA</scp>‐based drug–polymer applications: A review of experiments and theories

Xu, Yifan; Kim, Chang Soo; Saylor, David M.; Koo, Donghun

doi:10.1002/jbm.b.33648

Cited by 318 publications

(266 citation statements)

References 160 publications

(426 reference statements)

Supporting

Mentioning

244

Contrasting

Order By: Relevance

“…Several authors have demonstrated that the presence of drugs in PLGA-based DDSs influences the rate of matrix degradation. [44] Giunchedi et al showed a 27% increase in vitro of LA and GA monomers when diazepam was encapsulated into PLGA microspheres, compared to empty ones. [142] These results may be attributed to different functional groups of the drug that could react with carboxyl end groups of PLGA, accelerating the degradation process by autocatalysis.…”

Section: Drug Release From Poly(lactic-co-glycolic) Acid Delivery Sysmentioning

confidence: 99%

“…Adapted with permission. [44] increases the degradation rate of the polymer. [17] Despite the enrolment of enzymes in this process is still not clear, some authors believe that they are able to speed up PLGA degradation.…”

Section: Physical-chemical Propertiesmentioning

confidence: 99%

“…[5,17,31] As PLGA with low molecular weight is less hydrophobic, the processes such as water absorption, hydrolysis and erosion will increase. [44] It is estimated that a molecular weight of around 15 and 100 kDa corresponds to a degradation period of several weeks and months, respectively. [5] Low molecular weights are thus associated with a faster degradation rate of PLGA, producing a higher initial burst release and a shorter sustained release (Figure 2b).…”

Section: Physical-chemical Propertiesmentioning

confidence: 99%

See 2 more Smart Citations

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Martins

Sousa

Araújo

et al. 2017

Adv Healthcare Materials

206

133

View full text Add to dashboard Cite

Poly(lactic‐co‐glycolic) acid (PLGA) is one of the most versatile biomedical polymers, already approved by regulatory authorities to be used in human research and clinics. Due to its valuable characteristics, PLGA can be tailored to acquire desirable features for control bioactive payload or scaffold matrix. Moreover, its chemical modification with other polymers or bioconjugation with molecules may render PLGA with functional properties that make it the Holy Grail among the synthetic polymers to be applied in the biomedical field. In this review, the physical–chemical properties of PLGA, its synthesis, degradation, and conjugation with other polymers or molecules are revised in detail, as well as its applications in drug delivery and regeneration fields. A particular focus is given to successful examples of products already on the market or at the late stages of trials, reinforcing the potential of this polymer in the biomedical field.

show abstract

Section: Drug Release From Poly(lactic-co-glycolic) Acid Delivery Sysmentioning

confidence: 99%

Section: Physical-chemical Propertiesmentioning

confidence: 99%

Section: Physical-chemical Propertiesmentioning

confidence: 99%

See 1 more Smart Citation

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Martins

Sousa

Araújo

et al. 2017

Adv Healthcare Materials

206

133

View full text Add to dashboard Cite

show abstract

“…Moreover, PLGA is approved by the United States Food and Drug Administration (FDA) for clinical use in human beings, 37 and a lot of drug regents based on PLGA delivery system come forth for the treatment of various diseases. 38 This study further clarified that PLGA is compatible with AuNP-mediated siRNA delivery, particularly in the field of dental implantation. Furthermore, the strategy proposed is of favorable biocompatibility, easy to manipulate, and of controllable biodegradation rate.…”

Section: Plga-based Mirna Delivery System In Implant Functionalizationmentioning

confidence: 64%

Delivery of antagomiR204-conjugated gold nanoparticles from PLGA sheets and its implication in promoting osseointegration of titanium implant in type 2 diabetes mellitus

Liu¹,

Tan²,

Zhou³

et al. 2017

IJN

View full text Add to dashboard Cite

Impaired osseointegration of the implant remains the big hurdle for dental implant therapy in diabetic patients. In this study, the authors first identified that miR204 was strikingly highly expressed in the bone mesenchymal stem cells (BMSCs) of diabetic rats. Forced expression of miR204 repressed the osteogenic potential of BMSCs, while inhibition of miR204 significantly increased the osteogenic capacity. Moreover, the miR204 inhibitor was conjugated with gold nanoparticles (AuNP-antagomiR204) and dispersed them in the poly(lactic-co-glycolic acid) (PLGA) solution. The AuNP-antagomiR204 containing PLGA solution was applied for coating the surface of titanium implant. Electron microscope revealed that an ultrathin sheet was formed on the surface of the implant, and the AuNPs were evenly dispersed in the coated PLGA sheet. Cellular experiments revealed that these encapsulated AuNP-antagomiR204 were able to be released from the PLGA sheet and uptaken by adherent BMSCs. In vivo animal study further confirmed that the AuNP-antagomiR204 released from PLGA sheet promoted osseointegration, as revealed by microcomputerized tomography (microCT) reconstruction and histological assay. Taken together, this study established that miR204 misexpression accounted for the deficient osseointegation in diabetes mellitus, while PLGA sheets aided the release of AuNP-antagomiR204, which would be a promising strategy for titanium implant surface functionalization toward better osseointegration.

show abstract

“…One of the assumptions implicit in the preceding models is that the matrix material does not swell or degrade in vivo. However, many device applications employ materials that swell (Peppas, Hilt, Khademhosseini, & Langer, 2006) and/or degrade (Xu, Kim, Saylor, & Koo, 2017) by design. In these scenarios, one must consider not only transport of the leachable, but also the rate and extent of swelling as well as the change in properties as the material degrades.…”

Section: Future Opportunitiesmentioning

confidence: 99%

Advances in predicting patient exposure to medical device leachables

et al. 2020

Self Cite

View full text Add to dashboard Cite

Medical device materials contain chemicals that may pose toxicological concern(s) if released in sufficient quantities. Toxicological risk assessment approaches are increasingly being used in lieu of animal testing to address these concerns. Currently, these approaches rely primarily on in vitro extraction testing to estimate the potential for patients to be exposed to chemicals that may possibly leach out of device materials, but the clinical relevance of the test results is often ambiguous. Recent developments suggest physics‐based models can be used to provide more clinically relevant exposure estimates. However, the lack of data available to parameterize and validate these models presents a barrier to routine use. Herein, we provide an overview of these approaches, including considerations in developing and parameterizing exposure models, strategies that can be used to address the challenges associated with limited data, and potential future directions and improvements.

show abstract

Polymer degradation and drug delivery in PLGA‐based drug–polymer applications: A review of experiments and theories

Cited by 318 publications

References 160 publications

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

Delivery of antagomiR204-conjugated gold nanoparticles from PLGA sheets and its implication in promoting osseointegration of titanium implant in type 2 diabetes mellitus

Advances in predicting patient exposure to medical device leachables

Contact Info

Product

Resources

About